NDAORAL-21TABLET
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 26m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORTHO-NOVUM 1/80 21 is an oral contraceptive tablet combining mestranol (estrogen) and norethindrone (progestin) in a 21-day cycle formulation. It prevents pregnancy through suppression of ovulation and alteration of cervical mucus and endometrial environment. This product represents a legacy hormonal contraceptive from the Johnson & Johnson portfolio.
Post-LOE
Pre-launch lifecycle stage indicates limited commercial expansion; career opportunities center on legacy product management and regulatory compliance rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ORTHO-NOVUM 1/80 21 offers limited career growth in a mature, commoditized market with minimal innovation or expansion potential. Career trajectories typically involve compliance, regulatory maintenance, and cost optimization rather than strategic brand building or clinical advancement.
Regulatory Affairs SpecialistBrand Manager (Legacy Products)
Worked on ORTHO-NOVUM 1/80 21 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.